Clinical trials: Atrophy; Bone
Sarcopenia in Elderly, Frailty
Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness.
- Conditions
- Sarcopenia in Elderly, Frailty, Frailty/Sarcopenia, Frailty in Older Adults
- Trial name
- NCT06942182
- Testing
- Isomyosamine 250mg
- Volunteers
- 60 people
- Sponsor
- TNF Pharmaceuticals, Inc.
Bone Loss, Alveolar
A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction
The purpose of the study is to determine the efficacy and safety of the effects of a topical medication on bone remodeling after dental extraction, in order to establish whether such treatment can be a new therapeutic option for…
- Trial name
- XEOLAS (NCT05602493)
- Testing
- Soludronate®, sterile saline
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Xeolas Pharmaceuticals Limited
Alveolar Bone Loss, Periodontal Diseases
GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery
GUIDOR Growth Factor Enchanted Bone Graft Substitute (GFeBGS) when used in periodontal surgery will shown greater gum and bone regeneration when compare to bone graft substitute alone. Also, to find the optimal dose.
- Trial name
- NCT01728844
- Testing
- beta-tricalcium phosphate alone, GFeBGS 0.1%, GFeBGS 0.3%
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Sunstar Americas
Alveolar Bone Loss, Alveolar Ridge Pathology | Gingiva | Dental
Comparative Study of Gene-activated Bone Substitute and Xenogenic Bone Matrix in Alveolar Ridge Augmentation
The study aim is to compare the effectiveness of two bone substitutes, the gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene and xemogenic deproteinized bone matrix, mixed with…
- Trial name
- NCT04511689
- Testing
- gene-activated bone substitute mixed with autobone
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- Histograft Co., Ltd.
Osteopenia, Sarcopenia
Olive Oil Polyphenols, Vitamin D, Docosahexaenoic Acid (DHA) and Locomotor Function (PolivD3)
The present project hypothesizes that the potential protective effect of olive oil relies on its polyphenols profile (quality and quantity) and that it may be synergistic to other food components.
- Trial name
- PolivD3 (NCT01828944)
- Testing
- olive oil
- Where
- 2 sites in France
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Lesieur
Edentulous Maxilla, Maxillary Bone Loss
NobelZygoma TiUltra Implant System Study
The goal of this prospective study is to assess short term (12-months) clinical outcomes of NobelZygoma TiUltra implants and Multi-unit Abutment Xeal in the rehabilitation of participants with severely atrophic maxilla treated…
- Conditions
- Edentulous Maxilla, Maxillary Bone Loss, Atrophic Maxilla
- Trial name
- NCT07258940
- Testing
- NobelZygoma™ 0° CC TiUltra™implant ; NobelZygoma™ 45° Ext Hex TiUltra™ implant, Multi-Unit Abutment Xeal Zygoma Ext Hex RP; 17° Multi-Unit Abutment Xeal Zygoma Ext Hex RP; 45° Multi.Unit Abutment Xeal Zygoma CC RP; 60° Multi-Unit Abutment Xeal Zygoma CC RP
- Where
- 2 sites in Italy, Switzerland
- Volunteers
- 85 people
- Sponsor
- Nobel Biocare
Alveolar Bone Loss, Periodontal Bone Loss
Pilot Study on MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery
The purpose of the study is to gain experience of safety and efficacy with MD05 in man in alveolar bone regeneration.
- Trial name
- NCT00519155
- Testing
- MD05 and open flap debridement, Open flap debridement
- Where
- Hungary
- Volunteers
- 20 people
- Sponsor
- Scil Technology GmbH
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Menopause
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health
This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in…
- Trial name
- MPS (NCT04001088)
- Testing
- Probiotic
- Where
- 5 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Osteoporosis
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids
- Trial name
- NCT00799266
- Testing
- Zoledronic acid
- Where
- 12 sites in Australia, Canada and 4 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Increased Lordosis/Scoliosis, Hyporeflexia
Biomarker for Duchenne Muscular Dystrophy
International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.
- Conditions
- Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness
- Trial name
- BioDuchenne (NCT02994030)
- Where
- 12 sites in Albania, Egypt and 6 more
- Volunteers
- 103 people
- Sponsor
- CENTOGENE GmbH Rostock
Retinal Disease, Macular Degeneration
Stem Cell Ophthalmology Treatment Study
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease
- Trial name
- SCOTS (NCT01920867)
- Testing
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MD Stem Cells
Osteoporosis
1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
This 1-year open-label extension to CZOL446H2337 is designed to evaluate the safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids.
- Trial name
- NCT01197300
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia, Canada and 4 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Pseudoarthrosis
A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure)
The purpose os this study is to evaluate the safety and effectiveness of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of atrophic nonunion in long bones.
- Trial name
- Bonecure (NCT02483364)
- Testing
- HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Salvat
Multiple System Atrophy
Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy
The purpose of conducting phase 1 trial is to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells(CS10BR05) in subjects with Multiple System Atrophy.
- Trial name
- NCT03265444
- Testing
- CS10BR05
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Corestemchemon, Inc.
Preservation of Alveolar Bone Height With PLGA Bioscaffold
Radiographic Assessment of Bone Regeneration in Alveolar Sockets With PLGA Scaffold
After extraction of a tooth, the bony socket heals naturally but due to the absent of the tooth and any presence of support in the socket, bone resorption occur both vertically and bucco lingually or bucco palataly.
- Trial name
- NCT00836797
- Where
- 2 sites in India, Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bio-Scaffold International Pte Ltd
Jaw, Edentulous, Partially, Alveolar Bone Loss
Straumann Bone Ceramic Versus BioOss in Sinus Elevation
Straumann Bone Ceramic (SBC) and BioOss will be used as bone grafting materials when there is a need for bone augmentation in the posterior upper jaw. 9 months later the bone formation is evaluated.
- Trial name
- NCT00900822
- Testing
- Straumann Bone Ceramic, BioOss
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Institut Straumann AG
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Alveolar Bone Loss
Localized Alveolar Ridge Augmentation With Dental Implant
The purpose of this research study is to shorten the treatment time course for patients who are scheduled for surgery to have a dental implant(s) placed into the upper front part of their mouths and need to have more bone in…
- Trial name
- RidgeDI (NCT00991965)
- Testing
- INFUSE® Bone Graft
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Medtronic Spinal and Biologics
Periodontitis, Alveolar Bone Loss
Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)
This study aims to verify the effectiveness of Trafermin (recombinant human basic fibroblast growth factor) in stimulating regeneration of periodontal tissue lost by periodontitis and to evaluate the safety of such stimulation.
- Conditions
- Periodontitis, Alveolar Bone Loss, Periodontal Attachment Loss
- Trial name
- NCT00734708
- Testing
- Trafermin (genetical recombination)
- Where
- 21 sites in Japan
- Volunteers
- 328 people
- Sponsor
- Kaken Pharmaceutical